Evotec gets $5M milestone payment from Bristol Myers after FDA accepts new drug application
Source: SeekingAlpha
2025-11-12 03:07:06 ET
More on Bristol-Myers Squibb Company , Evotec SE
- Evotec SE 2025 Q3 - Results - Earnings Call Presentation
- Evotec SE (EVO) Q3 2025 Earnings Call Transcript
- Bristol-Myers Squibb: Way Too Cheap At 7x P/E
- FDA taps Richard Pazdur to lead key drugs office at agency
- Evotec SE reports Q3 results
Read the full article on Seeking Alpha
For further details see:
Evotec gets $5M milestone payment from Bristol Myers after FDA accepts new drug application
Evotec SE
NASDAQ: EVO
EVO Trading
0.2% G/L:
$2.50 Last:
39,177 Volume:
$2.53 Open:
EVO Latest News
January 08, 2026 01:50:00 am
Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access
January 02, 2026 12:30:00 am
Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations
December 08, 2025 01:20:00 am
Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz
December 04, 2025 02:50:00 am
Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome
EVO Stock Data
$320,181,806
73,171,742
N/A
9
N/A
Biotechnology & Life Sciences
Healthcare
DE
Hamburg
